Deal Details
Stellus Rx Receives Strategic Investment from WindRose
Summary
Stellus Rx (the “Company”) has received a strategic investment from WindRose Health Investors, LLC (“WindRose”). Terms of the transaction were not disclosed.
Baird served as exclusive financial advisor to Stellus Rx on this transaction.
About
Stellus Rx provides pharmacist-led patient support and dispensing solutions that sustainably improve patients' health outcomes and reduce total cost of care. The Company's technology-enabled teams connect with patients to optimize medications and guide them toward healthier behaviors. Through this work—including a care model that's especially impactful for people with chronic and complex conditions—Stellus Rx serves as a trusted partner for healthcare providers, payors, employers and other risk-bearing entities that seek to change the health and cost trajectory for patients nationwide. Stellus Rx is headquartered in Plano, Texas.WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. With over $7 billion under management, WindRose invests in companies throughout the United States. WindRose is headquartered in New York, New York.
CONTACT US TO LEARN MORE
- Date
- December 2025
- Company
- Stellus Rx
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Healthcare IT & Services
- Target Geography
- North America
- Acquiror Geography
- North America
Share
